Alfredo Puing, MD
Assistant ProfessorCards
About
Research
Publications
2025
Frailty by Chart Review Can Predict Infection in Kidney Transplant Recipients: A Multicenter Study through the AST IDCOP
Malinis M, Gan G, Deng Y, Abidi M, Benamu E, Jakharia N, Law N, Lee D, Nog R, Puing A, Sigler R, Taimur S, Theodoropoulos N, Schaenman J. Frailty by Chart Review Can Predict Infection in Kidney Transplant Recipients: A Multicenter Study through the AST IDCOP. American Journal Of Transplantation 2025, 25: s163. DOI: 10.1016/j.ajt.2025.07.357.Peer-Reviewed Original ResearchFrailty in Lung Transplant Candidates Predicts Post-Transplant Outcomes: A Multicenter Study
Schaenman J, Lum J, Arif S, Hardesty A, Hassouna H, Kennedy C, Lawson C, Nelson J, Pennington K, Saullo J, Tam P, Puing A, Malinis M, Taimur S, Levine D. Frailty in Lung Transplant Candidates Predicts Post-Transplant Outcomes: A Multicenter Study. American Journal Of Transplantation 2025, 25: s505. DOI: 10.1016/j.ajt.2025.07.1160.Peer-Reviewed Original ResearchCytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease
Soni K, Puing A. Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease. Viruses 2025, 17: 752. PMID: 40573343, PMCID: PMC12197619, DOI: 10.3390/v17060752.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCytomegalovirus colitisUlcerative colitisBowel diseaseCorticosteroid-refractory UCInflammatory bowel disease flaresInflammatory bowel disease symptomsCytomegalovirus reactivationColectomy rateImmunosuppressive agentsBiologic therapyTherapeutic challengeAntiviral therapyViral loadAdult patientsClinical outcomesTissue biopsiesChronic inflammationTreatment strategiesTissue PCRDiagnosis hingesCytomegalovirusActive infectionRisk factorsDiagnostic threshold
2024
Correction: Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center
So W, Khalak S, Ho S, Ross J, Dadwal S, Puing A, Nanayakkara D, Kaur A, Taplitz R, Dickter J. Correction: Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center. Infection 2024, 52: 2571-2571. PMID: 39382776, DOI: 10.1007/s15010-024-02410-x.Peer-Reviewed Original ResearchImplementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center
So W, Khalak S, Ho S, Ross J, Dadwal S, Puing A, Nanayakkara D, Kaur A, Taplitz R, Dickter J. Implementation and outcomes of beta-lactam allergy management protocol at a comprehensive cancer center. Infection 2024, 52: 2279-2286. PMID: 38907094, DOI: 10.1007/s15010-024-02274-1.Peer-Reviewed Original ResearchConceptsDelabel patientsLow riskHigh riskEmpirical antibiotic useLow-risk patientsBroad-spectrum antibioticsNon-verbal patientsPiperacillin-tazobactamAntibiotic historyMild rashAdult patientsClinical outcomesAntibiotic useAllergy labelsComprehensive cancer centerTest-doseCancer CenterMcNemar testPatientsAllergic reactionsInclusion criteriaBlaComfort careDelabelingManagement protocolHIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation
Dickter J, Aribi A, Cardoso A, Gianella S, Gendzekhadze K, Li S, Feng Y, Chaillon A, Laird G, Browning D, Ross J, Nanayakkara D, Puing A, Stan R, Lai L, Chang S, Kidambi T, Thomas S, Al Malki M, Nakamura R, Alvarnas J, Taplitz R, Dadwal S, Forman S, Zaia J. HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation. The New England Journal Of Medicine 2024, 390: 669-671. PMID: 38354149, PMCID: PMC10906479, DOI: 10.1056/nejmc2312556.Peer-Reviewed Original ResearchConceptsHIV-1 remissionHIV-1History of HIV-1 infectionAllogeneic hematopoietic-cell transplantationTreatment of acute myelogenous leukemiaHIV-1 infectionStem-cell transplantationHematopoietic-cell transplantationAcute myelogenous leukemiaA patientsMyelogenous leukemiaRemissionTransplantationLeukemiaInfection
2023
1267. Implementation and Outcomes of Beta-lactam Allergy Management Protocol at a Comprehensive Cancer Center
Khalak S, So W, Ho S, Ross J, Dadwal S, Puing A, Nanayakkara D, Taplitz R, Kaur A, Dickter J. 1267. Implementation and Outcomes of Beta-lactam Allergy Management Protocol at a Comprehensive Cancer Center. Open Forum Infectious Diseases 2023, 10: ofad500.1107. PMCID: PMC10677487, DOI: 10.1093/ofid/ofad500.1107.Peer-Reviewed Original ResearchBeta-lactam allergyDelabel patientsUnique patientsLow riskHigh riskEmpirical antibiotic useLow-risk patientsBroad-spectrum antibioticsNon-verbal patientsAztreonam usePiperacillin-tazobactamDays post-interventionProlonged hospitalizationClinical outcomesAntibiotic useAllergy labelsBeta-lactamComprehensive cancer centerCancer CenterGraded challengeMcNemar testPatientsExclusion criteriaInclusion criteriaMultiple admissions2617. Antiviral usage for herpes simplex virus (HSV) detected in bronchoalveolar lavage fluid (BALF) by polymerase chain reaction (PCR) in hematologic malignancy (HM) and solid organ malignancy (SOM) patients with pulmonary infiltrates; impact of infectious disease consultation (IDC) on antiviral stewardship
Fu C, Ross J, Ma H, Tegtmeier B, Dickter J, Nanayakkara D, Puing A, Kaur A, Taplitz R, Dadwal S. 2617. Antiviral usage for herpes simplex virus (HSV) detected in bronchoalveolar lavage fluid (BALF) by polymerase chain reaction (PCR) in hematologic malignancy (HM) and solid organ malignancy (SOM) patients with pulmonary infiltrates; impact of infectious disease consultation (IDC) on antiviral stewardship. Open Forum Infectious Diseases 2023, 10: ofad500.2230. PMCID: PMC10678139, DOI: 10.1093/ofid/ofad500.2230.Peer-Reviewed Original ResearchSolid organ malignanciesImpact of infectious disease consultationHerpes simplex virusHematologic malignanciesBronchoalveolar lavage fluidAntiviral usageAntiviral usePolymerase chain reactionHSV polymerase chain reactionOne-hundred-nine patientsHerpes simplex virus reactivationPositive testDose of acyclovirPositive polymerase chain reactionRetrospective chart reviewCohort of patientsInfectious disease consultationFisher's exact testHSV reactivationKruskal-Wallis testNo malignancyOrgan malignanciesPulmonary infiltratesHM patientsMucocutaneous infectionsStimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Chiuppesi F, Ortega-Francisco S, Gutierrez M, Li J, Ly M, Faircloth K, Mack-Onyeike J, La Rosa C, Thomas S, Zhou Q, Drake J, Slape C, Fernando P, Rida W, Kaltcheva T, Grifoni A, Sette A, Patterson A, Dempsey S, Ball B, Ali H, Salhotra A, Stein A, Nathwani N, Rosenzweig M, Nikolaenko L, Al Malki M, Dickter J, Nanayakkara D, Puing A, Forman S, Taplitz R, Zaia J, Nakamura R, Wussow F, Diamond D, Dadwal S. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy. Vaccines 2023, 11: 1492. PMID: 37766168, PMCID: PMC10538048, DOI: 10.3390/vaccines11091492.Peer-Reviewed Original ResearchHematopoietic cell transplantationCellular immune responsesImmune responseMonths post-vaccinationCell transplantationHematologic malignanciesHistorical cohortNeutralizing antibodiesSARS-CoV-2 antigen-specificSARS-CoV-2Post-hematopoietic cell transplantationCD4+ T lymphocytesPhase 2 clinical trialNucleocapsid (N) antigensRobust stimulationsHealthcare workersSARS-CoV-2 infectionHM patientsImmunocompetent individualsImmunocompromised populationsCOH04S1SARS-CoV-2 ST cellsT lymphocytesCellular immunityTreatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience
Tinajero J, Ngo D, Puing A, Koller P. Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience. Acta Haematologica 2023, 146: 490-495. PMID: 38156364, DOI: 10.1159/000533346.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcute myeloid leukemiaAcute myeloid leukemia induction chemotherapyAcute myeloid leukemia regimensSingle-center experienceAntiretroviral therapyHIV antiretroviral therapyInduction chemotherapyTreatment outcomesComplete remissionMyeloid leukemiaTreatment outcomes of acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationTherapy-related myelodysplastic syndromeOutcomes of acute myeloid leukemiaTreatment of acute myeloid leukemiaConcurrent antiretroviral therapyStem cell transplantationHuman immunodeficiency virusPotential drug interactionsMedian OSCR rateMyelodysplastic syndromeCell transplantationChemotherapy exposure
Academic Achievements & Community Involvement
Clinical Care
Overview
Alfredo Puing, MD, is an infectious diseases and internal medicine specialist who focuses on improving outcomes for patients with infectious diseases, especially those who are immunocompromised.
Dr. Puing received his medical training from Universidad Central del Ecuador and completed his residency in internal medicine at Saint Peter's University Hospital in New Jersey. He further specialized through fellowships in infectious diseases at the University of Texas Southwestern Medical Center and Stanford University. He is an assistant professor at Yale School of Medicine.
Clinical Specialties
Infectious Diseases; Internal Medicine
Fact Sheets
Sepsis
Learn More on Yale MedicinePediatric Sepsis
Learn More on Yale MedicinePneumonia
Learn More on Yale Medicine
Yale Medicine News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.